The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment.

Abstract:

:Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world's population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortality and all-cause mortality, being cured of CHC is associated with improvement in these outcomes. Older interferon-based regimens were complex and toxic and required 6-12 months of therapy, with cure rates averaging around 40-45% for HCV genotype 1. Newer interferon-free regimens are now available in the US, Europe, Japan and in other countries. These regimens have short durations, minimal side effects, low pill burden and efficacy approaching 90-100%. We may eventually see single-tablet regimens lasting no more than 4-6 weeks. This review will summarize the data regarding these interferon-free regimens, including Gilead's Harvoni (sofosbuvir/ledipasvir), AbbVie's Viekira Pak (paritaprevir/ritonavir/ombitasvir with dasabuvir), and Janssen's Olysio (simeprevir) with sofosbuvir. Some practical considerations as we move into an interferon-free era will also be discussed, such as patient adherence and drug-drug interactions.

authors

Lam BP,Jeffers T,Younoszai Z,Fazel Y,Younossi ZM

doi

10.1177/1756283X15587481

subject

Has Abstract

pub_date

2015-09-01 00:00:00

pages

298-312

issue

5

eissn

1756-283X

issn

1756-2848

pii

10.1177_1756283X15587481

journal_volume

8

pub_type

杂志文章,评审
  • Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone.

    abstract::Helicobacter pylori (H. pylori) are gram-negative bacteria that selectively colonizes the gastric mucosa. The prevalence of H. pylori infection varies from 20 to 50% in industrialized countries to over 80% in developing countries. The infection may persist lifelong without specific treatment. Prolonged infection and i...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X08094880

    authors: Lee YC,Liou JM,Wu MS,Wu CY,Lin JT

    更新日期:2008-09-01 00:00:00

  • Incidence of Clostridioides difficile infection in peripartum women: a retrospective cohort study.

    abstract:Background:The incidence of Clostridioides difficile infection (CDI) is increasing in the general population. Data on the epidemiology of CDI in peripartum women - a highly vulnerable patient population - is scarce. The objective of this study was to report the incidence of CDI in peripartum women. Methods:A single-ce...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284820942621

    authors: Saha S,Pardi R,Theiler RN,Pardi DS,Khanna S

    更新日期:2020-07-27 00:00:00

  • Diagnostic accuracy of i-scan image enhancement for real-time endoscopic diagnosis of small colorectal polyps: a meta-analysis.

    abstract:Objective:i-Scan is a digital image enhancement technology, reported to improve diagnostic performance during endoscopy. Previous studies have investigated the accuracy of i-scan for distinguishing between neoplastic and non-neoplastic colonic polyps and suggested diagnostic accuracy close to that required for use in r...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284818814948

    authors: Glover B,Patel N,Ashrafian H,Teare J

    更新日期:2018-12-06 00:00:00

  • Certolizumab pegol for the treatment of Crohn's disease.

    abstract::In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program sug...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X11413315

    authors: Schreiber S

    更新日期:2011-11-01 00:00:00

  • Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis.

    abstract:Background:Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn's disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and perioperative safety in VDZ-tr...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284818783614

    authors: Kotze PG,Ma C,Mckenna N,Almutairdi A,Kaplan GG,Raffals LE,Loftus EV Jr,Panaccione R,Lightner AL

    更新日期:2018-06-21 00:00:00

  • Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients.

    abstract:Background:The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan's demographic structure is becoming pronounced. In this study, we exami...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284819858511

    authors: Mori H,Suzuki H,Omata F,Masaoka T,Asaoka D,Kawakami K,Mizuno S,Kurihara N,Nagahara A,Sakaki N,Ito M,Kawamura Y,Suzuki M,Shimada Y,Sasaki H,Matsuhisa T,Torii A,Nishizawa T,Mine T,Ohkusa T,Kawai T,Tokunaga K,Tak

    更新日期:2019-07-04 00:00:00

  • Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.

    abstract::Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756283X16658251

    authors: Liu X,Yang Z,Latchoumanin O,Qiao L

    更新日期:2016-11-01 00:00:00

  • Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies.

    abstract:BACKGROUND:Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR12). The incidence of EOT+/SVR in patients with genotype 1 and...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X16672392

    authors: Malespin M,Benyashvili T,Uprichard SL,Perelson AS,Dahari H,Cotler SJ

    更新日期:2017-01-01 00:00:00

  • Gastrointestinal and liver diseases and atrial fibrillation: a review of the literature.

    abstract::Atrial fibrillation (AF) is the most common arrhythmia worldwide and is associated with significant morbidity and mortality. A number of risk factors have been associated with AF, though few studies have explored the association between gastrointestinal and liver diseases and AF. Additionally, AF and treatment for AF ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284819832237

    authors: Long MT,Ko D,Arnold LM,Trinquart L,Sherer JA,Keppel SS,Benjamin EJ,Helm RH

    更新日期:2019-04-02 00:00:00

  • Erratum for PMID 21180585.

    abstract::Erratum to 'Possible interactions between dietary fibres and 5-aminosalicyclic acid' by C Henriksen, S Hansen, I Nordgaard-Lassen, J Rikardt Anderson and P Madsen. Therapeutic Advances in Gastroenterology (2010) 3(1) 5-9 [DOI: 10.1177/ 1756283X09347810][This corrects the article on p. 5 in vol. 3.]. ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 已发布勘误

    doi:10.1177/1756283X10363751

    authors:

    更新日期:2012-09-01 00:00:00

  • Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation.

    abstract::In 2010, four independent groups almost simultaneously reported the association of the novel interleukin-1 (IL-1) family member, IL-33, with inflammatory bowel disease (IBD). The findings were remarkably consistent and demonstrated that IL-33 is markedly upregulated in, and specific to, ulcerative colitis (UC). In add...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X11410770

    authors: Pastorelli L,De Salvo C,Cominelli MA,Vecchi M,Pizarro TT

    更新日期:2011-09-01 00:00:00

  • Fully covered self-expandable metal stent in the treatment of postsurgical colorectal diseases: outcome in 29 patients.

    abstract:BACKGROUND:Self-expandable metal stent (SEMS) placement is a minimally invasive treatment for palliation of malignant colorectal strictures and as a bridge to surgery. However, the use of SEMS for benign colorectal diseases is controversial. The purpose of this retrospective study is to evaluate the efficacy and safety...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X15610052

    authors: Cereatti F,Fiocca F,Dumont JL,Ceci V,Vergeau BM,Tuszynski T,Meduri B,Donatelli G

    更新日期:2016-03-01 00:00:00

  • Effectiveness of endoscopic ultrasound-guided drainage for noncapsulated postoperative pancreatic collection.

    abstract:Background:Postoperative pancreatic collection (POPC) is a frequent complication after pancreatectomy. Although percutaneous drainage (PD) has been the treatment of choice for POPC with encapsulation, endoscopic ultrasound-guided transmural drainage (EUS-TD) was recently reported effective for this condition. The main ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284819884418

    authors: Tamura T,Kitano M,Kawai M,Tanioka K,Itonaga M,Kawaji Y,Nuta J,Hatamaru K,Yamashita Y,Kitahata Y,Miyazawa M,Hirono S,Okada KI,Yamaue H

    更新日期:2019-10-24 00:00:00

  • Screening colonoscopy bowel preparation: experience in an urban minority population.

    abstract:METHODS:Suboptimal bowel preparation, present in over 20% of colonoscopies, can severely compromise the effectiveness of the colonoscopy procedure. We surveyed 93 primarily urban minority men and women who underwent asymptomatic 'screening' colonoscopy regarding their precolonoscopy bowel-preparation experience. RESUL...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X13498661

    authors: Basch CH,Basch CE,Wolf RL,Zybert P,Lebwohl B,Shmukler C,Neugut AI,Shea S

    更新日期:2013-11-01 00:00:00

  • Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.

    abstract::Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X10369922

    authors: Sanger GJ,Chang L,Bountra C,Houghton LA

    更新日期:2010-09-01 00:00:00

  • Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial.

    abstract:BACKGROUND:Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D. METHODS:Patients received o...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X17726087

    authors: Cash BD,Pimentel M,Rao SSC,Weinstock L,Chang L,Heimanson Z,Lembo A

    更新日期:2017-09-01 00:00:00

  • Endoscopic Resection with Ligation Using a Multi-Band Mucosectomy System in Barrett's Esophagus with High-Grade Dysplasia and Intramucosal Carcinoma.

    abstract:BACKGROUND:Endoscopic therapy for early neoplasia in Barrett's esophagus (BE) is evolving. Endoscopic resection has an increasing role. We wanted to evaluate the safety and efficacy of multi-band ligation/resection [ER-L] without pre-injection in BE with high-grade dysplasia [HGD] and intramucosal carcinoma [IMCA]. ME...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X09346794

    authors: Bhat YM,Furth EE,Brensinger CM,Ginsberg GG

    更新日期:2009-11-01 00:00:00

  • Advances in therapeutic options for portal hypertension.

    abstract::Portal hypertension represents one of the major clinical consequences of chronic liver disease, having a deep impact on patients' prognosis and survival. Its pathophysiology defines a pathological increase in the intrahepatic vascular resistance as the primary factor in its development, being subsequently aggravated b...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284818811294

    authors: Vilaseca M,Guixé-Muntet S,Fernández-Iglesias A,Gracia-Sancho J

    更新日期:2018-11-25 00:00:00

  • Effective treatment of chronic radiation proctitis using radiofrequency ablation.

    abstract::Endoscopic argon plasma coagulation and bipolar electrocautery are currently preferred treatments for chronic radiation proctitis, but ulcerations and strictures frequently occur. Radiofrequency ablation (RFA) has been successful for mucosal ablation in the esophagus. Here we report the efficacy of RFA with the BarRx ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283x08103341

    authors: Zhou C,Adler DC,Becker L,Chen Y,Tsai TH,Figueiredo M,Schmitt JM,Fujimoto JG,Mashimo H

    更新日期:2009-01-01 00:00:00

  • Decision model analyses of upper endoscopy for gastric cancer screening and preneoplasia surveillance: a systematic review.

    abstract:Aims:Gastric cancer (GC) is the third leading cause of cancer death worldwide, but the burden of disease is not distributed evenly. GC screening routinely occurs in some high-incidence regions/countries and is generally cost-effective, which is attributed largely to the associated GC mortality reduction. In regions of ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284820941662

    authors: Canakis A,Pani E,Saumoy M,Shah SC

    更新日期:2020-07-16 00:00:00

  • Simultaneous analyses of carbohydrate-mediated serum GLP-1 and GLP-2 and duodenal receptor expression in children with and without celiac disease.

    abstract:Background:Variability in glucagon-like peptide (GLP)-1 and GLP-2 plasma concentrations has been suggested in Celiac disease (CD), with inconclusive results. We assessed the association between serum levels of GLP-1 and GLP-2 and their duodenal receptor expression in children with and without CD. Methods:This was a tw...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284819842756

    authors: Rachmiel M,Ben-Yehudah G,Shirin H,Broide E

    更新日期:2019-04-17 00:00:00

  • Targeting mucosal healing in Crohn's disease: what the clinician needs to know.

    abstract::In recent years, mucosal healing has emerged as a key therapeutic goal in the clinical management of patients with Crohn's disease, as it has been associated with improved long-term clinical outcomes. With the vast improvements in endoscopic imaging techniques and the increase in available treatment options, which rep...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284819856865

    authors: Klenske E,Bojarski C,Waldner M,Rath T,Neurath MF,Atreya R

    更新日期:2019-06-14 00:00:00

  • Bilio-pancreatic endoscopy during COVID-19 pandemic.

    abstract::On 31 December 2019, the WHO China Country Office was informed of cases of pneumonia of unknown etiology detected in Wuhan (Hubei Province of China). In January 2020, a new coronavirus named SARS-CoV2 was isolated and, since that time, SARS-CoV2 related disease (COVID-19) rapidly spread all over the world becoming pan...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284820935187

    authors: Bove V,Schepis T,Boškoski I,Landi R,Orlandini B,Pontecorvi V,Familiari P,Tringali A,Perri V,Costamagna G

    更新日期:2020-06-24 00:00:00

  • External validation of two prediction tools for patients at risk for recurrent Clostridioides difficile infection.

    abstract:Background:One in four patients with primary Clostridioides difficile infection (CDI) develops recurrent CDI (rCDI). With every recurrence, the chance of a subsequent CDI episode increases. Early identification of patients at risk for rCDI might help doctors to guide treatment. The aim of this study was to externally v...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284820977385

    authors: van Rossen TM,van Dijk LJ,Heymans MW,Dekkers OM,Vandenbroucke-Grauls CMJE,van Beurden YH

    更新日期:2021-01-09 00:00:00

  • Clinical outcome of patients with obscure gastrointestinal bleeding during antithrombotic drug therapy.

    abstract:Background:The clinical outcome of patients with obscure gastrointestinal bleeding (OGIB) during antithrombotic drug therapy has not been fully investigated. Methods:Patients who underwent video capsule endoscopy (VCE) for the investigation of OGIB at Okayama University Hospital from January 2009 to March 2016 were en...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X17746930

    authors: Kono Y,Kawano S,Okamoto Y,Obayashi Y,Baba Y,Sakae H,Abe M,Gotoda T,Inokuchi T,Kanzaki H,Iwamuro M,Kawahara Y,Okada H

    更新日期:2018-01-14 00:00:00

  • Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.

    abstract:Background and Aims:Efficacy of adalimumab in Crohn's disease (CD) has not been shown in China. The aim of this study was to evaluate the efficacy and safety of adalimumab in Chinese patients with CD. Methods:This 26-week, multicenter, phase III study evaluated patients with moderately to severely active CD and elevat...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284820938960

    authors: Chen B,Gao X,Zhong J,Ren J,Zhu X,Liu Z,Wu K,Kalabic J,Yu Z,Huang B,Kwatra N,Doan T,Robinson AM,Chen MH

    更新日期:2020-07-16 00:00:00

  • The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

    abstract::Gut microbiota is a compilation of microorganisms dwelling in the entire mammalian gastrointestinal tract. They display a symbiotic relationship with the host contributing to its intestinal health and disease. Even a slight fluctuation in this equipoise may be deleterious to the host, leading to many pathological cond...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X12454590

    authors: Bien J,Palagani V,Bozko P

    更新日期:2013-01-01 00:00:00

  • Automated endoscopic detection and classification of colorectal polyps using convolutional neural networks.

    abstract:Background:Recently the American Society for Gastrointestinal Endoscopy addressed the 'resect and discard' strategy, determining that accurate in vivo differentiation of colorectal polyps (CP) is necessary. Previous studies have suggested a promising application of artificial intelligence (AI), using deep learning in o...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284820910659

    authors: Ozawa T,Ishihara S,Fujishiro M,Kumagai Y,Shichijo S,Tada T

    更新日期:2020-03-20 00:00:00

  • Host-targeting therapies for hepatitis C virus infection: current developments and future applications.

    abstract::Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have undergone a revolution with the approval of multiple direct-acting antivirals (DAAs), which enable interferon-free treatments with consider...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284818759483

    authors: Crouchet E,Wrensch F,Schuster C,Zeisel MB,Baumert TF

    更新日期:2018-03-21 00:00:00

  • Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions.

    abstract::Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment for HCC remains largely unsatisfactory owing to its high recurrence rates and frequent accompanying cirrhosis. In addition, the unique immune environment of the liver promotes tolerance, which, in conjunction with immu...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756283X17722061

    authors: Kim HY,Park JW

    更新日期:2017-10-01 00:00:00